Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypoparathyroidism Clear all
Recruiting No phase listed Observational

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

NCT07345494
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
Palopegteriparatide
Drug
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
15 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated No phase listed Observational

Infection in DiGeorge Following CHD Surgery

NCT00278005
View directory record Official record
Conditions
DiGeorge Syndrome, Congenital Heart Defects
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 15 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy

NCT05579782
View directory record Official record
Conditions
Postoperative Hypoparathyroidism, Thyroid Disease, Thyroid Neoplasms, Thyroid Cancer
Interventions
NIRAF Detection Technology
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

NCT05680818
View directory record Official record
Conditions
Autosomal Dominant Hypocalcemia (ADH)
Interventions
Encaleret, Standard of Care
Drug · Dietary Supplement
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
16 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Oakland, California • Aurora, Colorado • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

Teriparatide for Postsurgical Hypoparathyroidism

NCT01171690
View directory record Official record
Conditions
Hypoparathyroidism Post-surgical
Interventions
Teriparatide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 21, 2014 · Synced Sep 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

A Registry for Participants With Chronic Hypoparathyroidism

NCT01922440
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
No intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
Not listed
Enrollment
1,339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
54
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

PTH-independent Effects of Encaleret

NCT05735015
View directory record Official record
Conditions
Post-Surgical Hypoparathyroidism
Interventions
encaleret
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

NCT05290493
View directory record Official record
Conditions
22q11 Deletion Syndrome
Interventions
NB-001, Placebo
Drug · Other
Lead sponsor
Nobias Therapeutics, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions

NCT02895906
View directory record Official record
Conditions
22q11.2 Deletion Syndrome
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes

NCT00004351
View directory record Official record
Conditions
Williams Syndrome, Angelman Syndrome, Prader-Willi Syndrome, Shprintzen Syndrome, Smith-Magenis Syndrome, DiGeorge Syndrome, Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
0 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome

NCT01127503
View directory record Official record
Conditions
Velo-cardio-facial Syndrome, Psychosis
Interventions
Metyrosine, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Does Treatment of Hypovitaminosis D Increase Calcium Absorption?

NCT00581828
View directory record Official record
Conditions
Osteoporosis, Osteopenia, Vitamin D Deficiency, Hypoparathyroidism, Hypercalciuria, Hypercalcemia
Interventions
Vitamin D
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years to 66 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hypoparathyroidism Natural History Study

NCT05793853
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 100 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34

NCT00001304
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
Synthetic Human Parathyroid Hormone 1-34, Calcitriol & Calcium
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
17 Years to 69 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism

NCT04009291
View directory record Official record
Conditions
Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Interventions
TransCon PTH, Placebo for TransCon PTH
Combination Product
Lead sponsor
Ascendis Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
Chicago, Illinois • Rochester, Minnesota • Great Neck, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Not applicable Interventional Results available

Thymus Transplantation Safety-Efficacy

NCT01220531
View directory record Official record
Conditions
Complete DiGeorge Anomaly, DiGeorge Syndrome, DiGeorge Anomaly, Complete DiGeorge Syndrome
Interventions
Cultured Thymus Tissue
Biological
Lead sponsor
Sumitomo Pharma Switzerland GmbH
Industry
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vitamin D Deficiency in Elderly African American Women in Central Texas

NCT01971411
View directory record Official record
Conditions
Vitamin D Deficiency, Osteoporosis, Osteopenia
Interventions
Calcium 500mg with 200 IU Vitamin D - 2 tablets daily, Blood levels of Vitamin D, Serum CTX, Mg, Ca++ and iPTH, Usual sun exposure documentation, Dietary intake of calcium, vitamin D, magnesium
Drug · Procedure · Behavioral
Lead sponsor
McLennan County Medical Education and Research Foundation
Other
Eligibility
70 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 3 Interventional Results available

HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism

NCT01199614
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
open-label PTH(1-84)
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 4 Interventional Results available

A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism

NCT02910466
View directory record Official record
Conditions
Chronic Hypoparathyroidism, Hypoparathyroidism
Interventions
rhPTH(1-84)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism

NCT07699471
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
Canvuparatide, Placebo
Drug · Other
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Homestead, Florida • Metairie, Louisiana • Las Vegas, Nevada + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Completed No phase listed Observational

Genetic Modifiers for 22q11.2 Syndrome

NCT00916955
View directory record Official record
Conditions
22q11.2 Deletion Syndrome
Interventions
Observation
Other
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism

NCT07805356
View directory record Official record
Conditions
Hypoparathyroidism, Chronic Hypoparathyroidism
Interventions
Encaleret, Placebo
Drug
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
16 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
4
States / cities
Reno, Nevada • Greenville, North Carolina • Morehead City, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 3 Interventional Results available

Effects of PTH Replacement on Bone in Hypoparathyroidism

NCT00395538
View directory record Official record
Conditions
Hypoparathyroidism, DiGeorge Syndrome
Interventions
PTH 1-34
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 3 Interventional Results available

A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)

NCT01297309
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
NPSP558
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
14
States / cities
Lakewood, California • Jacksonville, Florida • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Sep 17, 2026, 5:14 AM EDT